Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959)

doi:10.1186/s12916-019-1422-6

	Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959)
	Dong,Di1,2,3 ; Zhang,Fan 2,4; Zhong,Lian-Zhen 1,3; Fang,Meng-Jie 1,3; Huang,Cheng-Long 2; Yao,Ji-Jin 4; Sun,Ying 2; Tian,Jie1,5 ; Ma,Jun 2; Tang,Ling-Long 2
刊名	BMC Medicine
	2019-10-23
卷号	17 期号:1
关键词	Individualized imaging biomarker Induction chemotherapy Survival benefit Treatment decision Locoregionally advanced nasopharyngeal cancer
ISSN号	1741-7015
DOI	10.1186/s12916-019-1422-6
通讯作者	Tian,Jie(jie.tian@ia.ac.cn) ; Ma,Jun(majun2@mail.sysu.edu.cn) ; Tang,Ling-Long(tangll@sysucc.org.cn)
英文摘要	AbstractBackgroundIn locoregionally advanced nasopharyngeal carcinoma (LANPC) patients, variance of tumor response to induction chemotherapy (ICT) was observed. We developed and validated a novel imaging biomarker to predict which patients will benefit most from additional ICT compared with chemoradiotherapy (CCRT) alone.MethodsAll patients, including retrospective training (n?=?254) and prospective randomized controlled validation cohorts (a substudy of NCT01245959, n?=?248), received ICT+CCRT or CCRT alone. Primary endpoint was failure-free survival (FFS). From the multi-parameter magnetic resonance images of the primary tumor at baseline, 819 quantitative 2D imaging features were extracted. Selected key features (according to their interaction effect between the two treatments) were combined into an Induction Chemotherapy Outcome Score (ICTOS) with a multivariable Cox proportional hazards model using modified covariate method. Kaplan-Meier curves and significance test for treatment interaction were used to evaluate ICTOS, in both cohorts.ResultsThree imaging features were selected and combined into ICTOS to predict treatment outcome for additional ICT. In the matched training cohort, patients with a high ICTOS had higher 3-year and 5-year FFS in ICT+CCRT than CCRT subgroup (69.3% vs. 45.6% for 3-year FFS, and 64.0% vs. 36.5% for 5-year FFS; HR?=?0.43, 95% CI?=?0.25–0.74, p?=?0.002), whereas patients with a low ICTOS had no significant difference in FFS between the subgroups (p?=?0.063), with a significant treatment interaction (pinteraction?
语种	英语
出版者	BioMed Central
WOS记录号	BMC:10.1186/S12916-019-1422-6
内容类型	期刊论文
源URL	[http://ir.ia.ac.cn/handle/173211/26362]
专题	中国科学院自动化研究所
通讯作者	Tian,Jie; Ma,Jun; Tang,Ling-Long
作者单位	1. 2. 3. 4. 5.
推荐引用方式 GB/T 7714	Dong,Di,Zhang,Fan,Zhong,Lian-Zhen,et al. Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959)[J]. BMC Medicine,2019,17(1).
APA	Dong,Di.,Zhang,Fan.,Zhong,Lian-Zhen.,Fang,Meng-Jie.,Huang,Cheng-Long.,...&Tang,Ling-Long.(2019).Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959).BMC Medicine,17(1).
MLA	Dong,Di,et al."Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959)".BMC Medicine 17.1(2019).